During the last session, BioXcel Therapeutics Inc (NASDAQ:BTAI)’s traded shares were 96706.0, with the beta value of the company hitting -0.13. At the end of the trading day, the stock’s price was $1.73, reflecting an intraday gain of 5.49% or $0.09. The 52-week high for the BTAI share is $25.12, that puts it down -1352.02 from that peak though still a striking 32.37% gain since the share price plummeted to a 52-week low of $1.17. The company’s market capitalization is $10.47M, and the average intraday trading volume over the past 10 days was 0.17 million shares, and the average trade volume was 302.99K shares over the past three months.
BioXcel Therapeutics Inc (BTAI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.50. BTAI has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.13.
BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information
BioXcel Therapeutics Inc (BTAI) registered a 5.49% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 5.49% in intraday trading to $1.73, hitting a weekly high. The stock’s 5-day price performance is -3.35%, and it has moved by 20.14% in 30 days. Based on these gigs, the overall price performance for the year is -92.11%. The short interest in BioXcel Therapeutics Inc (NASDAQ:BTAI) is 0.52 million shares and it means that shorts have 1.38 day(s) to cover.
The consensus price target of analysts on Wall Street is $10, which implies an increase of 82.7% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1 and $25 respectively. As a result, BTAI is trading at a discount of -1345.09% off the target high and 42.2% off the low.
BioXcel Therapeutics Inc (BTAI) estimates and forecasts
In the rating firms’ projections, revenue will decrease -26.02% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 200k as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 300k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.1M and 214k respectively. In this case, analysts expect current quarter sales to shrink by -81.88% and then jump by 40.19% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 6.20%. While earnings are projected to return 73.67% in 2025, the next five years will return 53.72% per annum.
BTAI Dividends
BioXcel Therapeutics Inc is due to release its next quarterly earnings on 2025-May-12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
BioXcel Therapeutics Inc (NASDAQ:BTAI)’s Major holders
BioXcel Therapeutics Inc insiders own 8.64% of total outstanding shares while institutional holders control 11.02%, with the float percentage being 12.06%. ARMISTICE CAPITAL, LLC is the largest shareholder of the company, while 38.0 institutions own stock in it. As of 2024-06-30, the company held over 2.99 million shares (or 0.4638% of all shares), a total value of $3.82 million in shares.
The next largest institutional holding, with 2.21 million shares, is of FMR LLC’s that is approximately 0.3424% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $2.82 million.
